|
Match
|
Document |
Document Title |
|
|
6572889 |
Controlled release solid dosage carbamazepine formulations
A polymer or copolymer composition derived from one or more unsaturated carboxylic acids that is cross-linked and carbamazepine in conjunction with conventional materials such as fillers,...
|
|
|
6573238 |
Method for producing sustained-release formulations
Methods for preparing biodegradable microparticles are provided. Also provided are microparticles prepared by the method which include IGF-1 entrapped therein. The microparticles allow for...
|
|
|
6569456 |
Osmotic device containing diltiazem and an ACE inhibitor or diuretic
The present invention provides an osmotic device containing controlled release diltiazem in the core in combination with a rapid release ACE inhibitor, or diuretic, in an external coat. The...
|
|
|
6565883 |
Controlled release oral compositions comprising rivastigmine
Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.
|
|
|
6562835 |
Method for the treatment of urinary incontinence
Urinary incontinence is alleviated in a mammal by administering to the mammal a urinary incontinence alleviating amount of dextromethorphan, dextrorphan, their mixtures and/or pharmaceutically...
|
|
|
6558699 |
High drug load immediate and modified release oral dosage formulations and processes for their manufacture
This invention relates to high drug load granulation of (E)-α-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-
yl]methylene-2-thiophenepropionic acid in the anhydrous form, a process for its...
|
|
|
6558701 |
Multilayer tablet for administering a fixed combination of tramadol and diclofenac
A multilayer tablet for oral administration containing at least one Tramadol layer including Tramadol or a physiologically acceptable salt thereof; at least one diclofenac layer including...
|
|
|
6558700 |
Multiple-unit sustained release tablets
A multiple-unit sustained release tablet characterized by consisiting of a granular part and a powdery part, each granule comprising a matrix composed of a water-insoluble polymer and an active...
|
|
|
6555136 |
Pharmaceutical dosage form for pulsatile delivery of methylphenidate
Novel pharmaceutical dosage forms provide for pulsatile delivery of methylphenidate, i.e., release encapsulated drug in spaced apart “pulses.” The dosage forms are comprised of first, second...
|
|
|
6555127 |
Multi-spike release formulation for oral drug delivery
Methylphenidate or other drugs are provided in a formulation for oral administration that releases the drug in two or more pharmacokinetic spikes, by combining different release forms in a single...
|
|
|
6551618 |
Compositions and methods for delivery of agents for neuronal regeneration and survival
Devices useful in the delivery of DNA encoding neurotrophic agents, anti-fibrotic agents, and related compositions are disclosed herein for use in the treatment of central and/or peripheral nervous...
|
|
|
6548084 |
Controlled release compositions
A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxetine.
|
|
|
6548083 |
Prolonged release active agent dosage form adapted for gastric retention
The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent formulation to a fluid...
|
|
|
6548082 |
Methods for treating apnea and apnea disorders using optically pure R(&plus ) ondansetron
Methods for the treatment, management, or prevention of apnea and apnea disorders, or symptoms thereof, using a therapeutically effective amount of substantially optically pure R(+) ondansetron, or...
|
|
|
6544553 |
Dosage forms and methods for oral delivery of progesterone
Provided is an oral dosage form suitable to deliver a combined dosage of progesterone and which upon delivery through the gastrointestinal tract provides a blood concentration of from about 0.1...
|
|
|
6544555 |
Antibiotic product, use and formulation thereof
An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the C max for the antibiotic product being reached in less than about twelve...
|
|
|
6544554 |
Regulated release preparations
Controlled-release formulation having such a portion that the core and a drug release layer each of which has been formulated to effect rapid or gradual release of at least one drug the release of...
|
|
|
6537527 |
Skin lightening compositions
This invention relates to compositions, compounds, and methods for lightening skin, using active compounds having the general structure: wherein each X is halo; m is 1 to 4; each R′ and R″...
|
|
|
6534089 |
Uniform drug delivery therapy
The invention disclosed pertains to a novel delivery system comprising an agent formulation and means for dispensing the agent formulation from the delivery system.
|
|
|
6531151 |
Composition containing hydroxypropylmethylcellulose and/or ethylcellulose as disintegrants and process for producing it
Pharmaceutical composition comprising at least one active ingredient and hydroxypropylmethylcellulose, highly substituted hydroxypropylcellulose, and/or ethylcellulose as disintegrants, in...
|
|
|
6531152 |
Immediate release gastrointestinal drug delivery system
A gastrointestinal delivery system is provided. The system comprises a drug in combination with a swellable core material, the core being surrounded by a water-insoluble or relatively...
|
|
|
6528539 |
Stable formulation containing fumagillin
The invention relates to a stable fumagillin formulation and to the method of use thereof in treating and/or combating intestinal infections.
|
|
|
6524619 |
Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
The invention defines interdependent biofactors and biomolecules, and clinically useful formulations that are comprised of them. The active agents are demonstrated to be complementary in their...
|
|
|
6524618 |
Directly compressible extended-release matrix formulation for metformin hydrochloride
An extended-release matrx formulation capable of being directly compressed into tablets comprising metformin hydrochloride blended with specific excipients. The excipients used in the formulation...
|
|
|
6524606 |
Bioerodible polyorthoesters containing amine groups
Bioerodible polyorthoesters useful as orthopedic implants or vehicles for the sustained delivery of pharmaceutical, cosmetic and agricultural agents contain amine functionalities and α-hydroxy...
|
|
|
6521254 |
Single-dose antihistamine/decongestant formulations for treating rhinitis
Pharmaceutical dosage forms for oral administration of an antihistamine and a decongestant are disclosed. The dosage forms provide an antihistamine in an amount and formulation to exhibit...
|
|
|
6521247 |
Dual iron containing nutritional supplement
The present invention relates to a nutritional supplement which comprises two different iron compounds, namely a rapidly dissolving iron compound and a slowly dissolving iron compound. The tablet...
|
|
|
6521255 |
Osmotic device containing ranitidine and a prokinetic agent
The present invention provides an osmotic device containing controlled release ranitidine in the core in combination with a prokinetic agent in a rapid release external coat. A wide range of...
|
|
|
6521253 |
Immediate release tablet
A new oral IR formulation in solid form for a low molecular weight thrombin inhibitor having pH dependant dissolution, characterized in that the formulation comprises a filler or a combination of...
|
|
|
6517869 |
Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the delivery of a bioactive agent via tissue and cellular uptake
A biodegradable, positively-charged aminoalkyl polyester polymer for the delivery of bioactive agents, such as DNA, RNA, oligonucleotides is disclosed. Biologically active moieties, such as drugs,...
|
|
|
6517866 |
Sertraline salts and sustained-release dosage forms of sertraline
Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is...
|
|
|
6517871 |
Bioenhanced formulations comprising eprosartan in oral solid dosage form
This invention relates to bioenhanced formulations comprising eprosartan or eprosartan mesylate in the amorphous form, a process for its production, compositions containing the compound and methods...
|
|
|
6515010 |
Carvedilol methanesulfonate
This invention relates to carvedilol methanesulfonate, compositions containing this compound and methods of using carvedilol methanesulfonate to treat hypertension, congestive heart failure and...
|
|
|
6514533 |
Device for the sustained release of aggregation-stabilized, biologically active agent
A device for the sustained release in vivo of a water soluble, biologically active agent wherein the agent is susceptible to aggregation comprising a drug delivery device and...
|
|
|
6514530 |
Dosage form comprising means for changing drug delivery shape
A dosage form is disclosed comprising means for delivering essentially a total dose of drug.
|
|
|
6514531 |
Controlled-release dosage forms comprising zolpidem or a salt thereof
The present invention relates to controlled-release dosage forms of zolpidem or salts thereof adapted to release zolpidem over a predetermined time period, according to a biphasic profile of...
|
|
|
6509037 |
Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof
The present invention provides a novel sustained release composition and method for making such a composition of diclofenac and its pharmaceutically acceptable salts. The composition of the present...
|
|
|
6506409 |
Dosage device
A method of making a dosage device comprises mixing a suspension concentrate comprising at least one active ingredient which is in solid form at 25° C., and which has an average particle size of...
|
|
|
6506408 |
Implantable or insertable therapeutic agent delivery device
Disclosed herein is an implantable or insertable therapeutic agent delivery device comprising a coating material provided on at least a portion of said device, said coating material prohibiting...
|
|
|
6500459 |
Controlled onset and sustained release dosage forms and the preparation thereof
A pharmaceutical composition for controlled onset and sustained release of an active ingredient, said composition comprising: (i) a core comprising: (a) an active ingredient; (b) a hydrophilic...
|
|
|
6500455 |
Tolperison-containing, pharmaceutical preparation for oral administration
A pharmaceutical preparation containing Tolperison or a salt thereof as an active ingredient in the form of a racemic mixture which can be a 50/50/-racemat or a racemat with the perponderant...
|
|
|
6500454 |
Timed, sustained release systems for propranolol
A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles...
|
|
|
6497901 |
Resorbable matrices for delivery of bioactive compounds
This invention relates generally to the production and use of inorganic-conditioning agent complexes for the controlled release of compounds including medicinals. Advantageously, the inorganic used...
|
|
|
6495162 |
Controlled release oral tablet having a unitary core
A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and...
|
|
|
6491948 |
Composition comprising isoquercetin and ascorbic acid in a sustained release form
The present invention relates to novel, orally administered compositions comprising two redox systems: reduced ascorbic acid in a sustained release form and oxidized isoquercetin with an increased...
|
|
|
6491945 |
Hydrocodone therapy
A hydrocodone composition, a hydrocodone dosage form, and a method of administering hydrocodone are disclosed and indicated for hydrocodone therapy.
|
|
|
6491949 |
Osmotic device within an osmotic device
The delivery devices described herein are capable of delivering one or more active substances by osmotic pumping through preformed passageways. An osmotic device according to the invention includes...
|
|
|
6491952 |
Cholesterol lowering composition
The present invention concerns a composition containing a cholesterol lowering component such as β-sitosterol and/or β-sitostanol in a monomolecular, low associated or “cluster” form, where a...
|
|
|
6488962 |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
The retention of oral drug dosage forms in the stomach is improved by using swellable dosage forms that are shaped in a manner that will prevent them from inadvertently passing through the pylorus...
|
|
|
6485746 |
Controlled-release sedative-hypnotic compositions and methods related thereto
Controlled-release formulations providing a “pulsed” plasma profile of a sedative-hypnotic compound having a particularly short half-life are provided. The formulation contains a...
|